We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). Show more
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial...
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and...
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late...
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.49 | -2.77306168647 | 17.67 | 18.51 | 15.96 | 446982 | 17.2239067 | CS |
| 4 | -0.46 | -2.60770975057 | 17.64 | 26 | 15.96 | 524678 | 20.45493699 | CS |
| 12 | 1.22 | 7.64411027569 | 15.96 | 26 | 10.9001 | 268302 | 18.88015192 | CS |
| 26 | 5.18 | 43.1666666667 | 12 | 26 | 9.8 | 199748 | 16.50566976 | CS |
| 52 | -2.63 | -13.2761231701 | 19.81 | 26 | 9.8 | 180218 | 17.52753393 | CS |
| 156 | -7.02 | -29.0082644628 | 24.2 | 26 | 9.8 | 174345 | 17.95506145 | CS |
| 260 | -7.02 | -29.0082644628 | 24.2 | 26 | 9.8 | 174345 | 17.95506145 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
